康泰生物(300601.SZ):2022年度預虧0.76億-1.5億元、同比盈轉虧
格隆匯1月10日丨康泰生物(300601.SZ)公佈,預計2022年度歸屬於上市公司股東的淨虧損0.76億元-1.5億元,上年同期為盈利12.63億元;扣除非經常性損益後的淨虧損1.26億元-2億元,上年同期為盈利11.91億元。
2022年度業績變動的主要原因如下:1、報吿期內,公司根據年度經營計劃積極開展各項工作,進一步加強市場銷售及推廣工作,公司常規疫苗(不含新冠疫苗)銷售收入同比增長86%,其中主要產品四聯苗、乙肝疫苗、13價肺炎球菌多糖結合疫苗銷售收入增長顯著。
2、業績虧損,主要原因系報吿期內由於國內外新冠疫苗接種環境發生重大變化,公司新冠疫苗銷量較去年大幅下滑,同時公司按照企業會計準則的有關規定和要求,對2022年度存在減值跡象的新冠疫苗相關庫存商品、原輔料、自制半成品、生產設備及新冠滅活疫苗開發支出計提資產減值準備78518.41萬元,新冠滅活疫苗Ⅲ期臨牀研發支出費用化處理30251.75萬元;前述因素合計減少利潤總額108770.16萬元,考慮加計扣除影響,減少淨利潤81592.49萬元。
報吿期預計非經常性損益對淨利潤的影響金額約5010.31萬元,去年同期非經常性損益的金額為7279.96萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.